COPENHAGEN: Danish drugmaker Bavarian Nordic, the lone laboratory manufacturing a licensed vaccine against monkeypox, has announced new supply deal to with Canada’s public health agency that is worth about $234 million, with an additional $180 million in contract options for further doses over 10 years.
